Physician profile
John Edward Bishop
NPI 1063408458
$2,320.15
in general payments reported to CMS, 2019-2025
21 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $242 · 2021: $150 · 2022: $574 · 2023: $427 · 2024: $279 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $321.43 | 2023-2025 | Livmarli |
| Biogen, INC. | $268.83 | 2022-2024 | Spinraza |
| Travere Therapeutics, INC. | $225.29 | 2021-2022 | |
| Glaxosmithkline, LLC. | $216.01 | 2019-2023 | Bexsero |
| Biomerieux INC | $173.91 | 2023-2025 | Filmarray Torch Module |
| Lnhc, INC | $124.69 | 2025 | Zelsuvmi |
| Ipsen Biopharmaceuticals, INC | $124.69 | 2025 | Bylvay |
| Abbvie INC. | $124.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2022 | |
| Sun Pharmaceutical Industries INC. | $109.17 | 2020 | |
| Pharming Healthcare, INC. | $102.60 | 2023 | Joenja |
| Shire North American Group INC | $97.33 | 2019 | |
| Phadia US INC. | $74.47 | 2022 | |
| Genentech, INC. | $72.89 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.21 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.01 | 2020-2021 | |
| Alcon Vision LLC | $21.49 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Allergan, INC. | $13.97 | 2020 | |
| Horizon Therapeutics Plc | $13.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.